Page 9 - Sun Pharma
FDA observation, forensic audit by Sebi may keep Sun Pharma under pressure
Halol plant observations add to worries on the extent of upsides from specialty drugs
 "FDA observation, forensic audit by Sebi may keep Sun Pharma under pressure")
Sun Pharma declines nearly 3% as Halol facility gets 8 US FDA observations
The company said it was preparing the response to the observations, which will be submitted to the US FDA within 15 business days
 "Sun Pharma declines nearly 3% as Halol facility gets 8 US FDA observations")
Sun Pharma gets partial relief from US court in litigation on generic drugs
Shares of the company on Monday ended 2.18 per cent lower at Rs 440 apiece on the BSE
 "Sun Pharma gets partial relief from US court in litigation on generic drugs")
Specialty drugs, domestic growth prospects positives for Sun Pharma stock
While pricing pressure in the US generics is also stabilising, the specialty products that Sun Pharma has been investing in are seen as a growth driver of its US business
 "Specialty drugs, domestic growth prospects positives for Sun Pharma stock")
Top biz headlines today: SC Maharashtra order, Zee chairman quits & more
From DGCA directing IndiGo to replace unmodified P&W engines to Karvy denying fund abuse charges, here are the top headlines of the day.
 "Top biz headlines today: SC Maharashtra order, Zee chairman quits & more")
Price-fixing charges: Sun Pharma in talks with US to end anti-trust probe
Prosecutors have been investigating allegations that generic drugmakers conspired to prop up the prices of certain widely used medications for more than five years
 "Price-fixing charges: Sun Pharma in talks with US to end anti-trust probe")
Nifty Pharma index hits two-month high; Sun Pharma surges 7%
Among other individual stocks, Lupin, Dr Reddy's Laboratories, Divi's Laboratories and Aurobindo Pharma from the Nifty Pharma index were up 3 per cent each on the NSE.
 "Nifty Pharma index hits two-month high; Sun Pharma surges 7%")
Here's why Sun Pharma is betting on Japan when peers are losing interest
Recently, Japan's sixth largest generic player Lupin said it felt that the annual price cuts made the market unattractive and it would continue to grow in single digits in value terms
Top 10 biz headlines: Sun Pharma, I-T dept seeks tax mop-up, and more
From PSU general insurance companies to Piramal's financial commitments, here are the top 10 business headlines for the day
 "Top 10 biz headlines: Sun Pharma, I-T dept seeks tax mop-up, and more")
Sun Pharmaceutical bullish on Japanese market as peers lose interest
Most Indian players have exited Japan over the past decade. Ranbaxy was one of the early entrants.
Sun Pharma posts Rs 1,433-crore pre-tax profit in Q2, meets estimates
Mumbai, 7 NovemberSun Pharmaceutical Industries' second quarter (Q2; July-September) results are mostly in line with Street expectations, with pre-tax profit of Rs 1,433.4 crore. It was Rs 111.9 crore in the corresponding quarter last year that was impacted by settlements related to anti-trust litigation on its Modafinil drug in the US. Net profit for the quarter is Rs 1,064 crore, with resulting net profit margin at 13.4 per cent. This is against a net loss of Rs 269.6 crore a year before. Adjusted for the exceptional item of Rs 1,214 crore for Q2 last year (Modafinil settlement), net profit growth was 12.6 per cent, the company said. Sales or income from operations was Rs 7,949 crore, up 16 per cent year-on-year (YoY). The India business saw 35 per cent growth YoY to Rs 2,515 crore, while US finished dosage sales remained flat YoY at $339 million. Taro, the US subsidiary, had sales of $161 mn, up one per cent over Q2 last year. Emerging market sales grew only three per cent to ...
 "Sun Pharma posts Rs 1,433-crore pre-tax profit in Q2, meets estimates")
Sun Pharma ties up with AstraZeneca to sell novel oncology drugs in China
Sun Pharma has been working out deals through this year to gain foothold in the Chinese market
 "Sun Pharma ties up with AstraZeneca to sell novel oncology drugs in China")
Sun Pharma climbs over 5% on deal with AstraZeneca, pares gains later
The agreement will be announced later in the day at the China International Import Expo (CIIE) in Shanghai.
Sun Pharma, Britain's AstraZeneca join to distribute cancer drugs in China
The financial terms of the agreement, which has an initial tenure of 10 years, were not disclosed
Specialty drugs essential for re-rating of Sun Pharma stock, say analysts
Analysts say, Tuesday's launch of ophthalmic specialty product Cequa can achieve peak sales of $100-125 million per annum
 "Specialty drugs essential for re-rating of Sun Pharma stock, say analysts")
Sun Pharmaceutical launches Cequa to treat dry eye disease in US market
Cequa is indicated to increase tear production in patients with dry eye, Sun Pharma said
 "Sun Pharmaceutical launches Cequa to treat dry eye disease in US market")
Symptoms of success
Soma Das has been able to capture brilliantly the essence of Dilip Shanghvi through countless stories
 "Symptoms of success")
Sun Pharma slides 4% after Co says forensic audit by Sebi underway
A forensic audit has been ordered by Sebi w.r.t. the financial statements of the company for the financial years ending FY16, FY17, and FY18.
 "Sun Pharma slides 4% after Co says forensic audit by Sebi underway")
Sebi orders forensic audit of Sun Pharma financial statements from FY16-18
Sun Pharma, however, did not provide any specific details on the reasons for the Securities and Exchange Board of India to order the forensic audit
Sun Pharma slides 4% on report of Sebi ordering forensic audit
The audit has been ordered based on allegations of corporate governance and tax-related offences and securities market-related violations by the company
